Phase I study evaluating the interaction of MK-3682 (IDX21437) with grazoprevir and MK-8408 in healthy subjects

Trial Profile

Phase I study evaluating the interaction of MK-3682 (IDX21437) with grazoprevir and MK-8408 in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2015

At a glance

  • Drugs Grazoprevir (Primary) ; Ruzasvir (Primary) ; Uprifosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Apr 2015 New trial record
    • 08 Apr 2015 Results will be presented at The International Liver Congress 2015, according to a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top